Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.546    -0.034 (-5.86%)
Bid:
0.55
Ask:
0.60
Spread: 0.05 (9.091%)
Market Cap: £3.17m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

Placing

14 Sep 2012 07:00

RNS Number : 2542M
Futura Medical PLC
14 September 2012
 



For immediate release

14 September 2012

 

Futura Medical plc

("Futura" or "the Company")

Placing to raise £2.08 million

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce a Placing by Nomura Code Securities Limited in which gross proceeds of £2.08 million are being raised through the issue of 3,654,969 new ordinary shares of 0.2 pence each in Futura ("New Ordinary Shares") to existing institutional investors at a price of 57 pence per share. The Placing represents approximately 5% of the Company's issued share capital.

The £2.0 million net proceeds of the Placing, which is underwritten by Nomura Code Securities Limited, will be used to provide additional working capital. The Placing strengthens the balance sheet and will assist the Company in its out-licensing negotiations as well as the ongoing development of its product pipeline.

The New Ordinary Shares will rank pari passu with the existing ordinary shares of the Company. Application has been made to the London Stock Exchange and it is anticipated that trading of the New Ordinary Shares will commence on AIM at 8:00am on 19 September 2012.

Futura's total issued share capital following the admission of the New Ordinary Shares will be 77,369,081. The total number of voting rights in the Company will be 77,369,081.

James Barder, Futura's Chief Executive, said: "We're delighted to have completed this oversubscribed fundraising and by the support that we have received from our existing institutional shareholders."

For any further information please contact:

Futura Medical plc

+ 44 (0) 1483 685 670

James Barder, Chief Executive Officer

Mail to: James.Barder@futuramedical.com

www.futuramedical.com

 

Nomura Code Securities Limited

+ 44 (0) 20 7776 1200

Phil Walker / Giles Balleny

 

Buchanan

+ 44 (0) 20 7466 5000

Mark Court / Fiona Henson / Sophie Cowles

 

 

Notes to editors:

 

About Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

 

www.futuramedical.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFXLLFLKFBBBV
Date   Source Headline
17th Jul 20237:00 amRNSFutura/Haleon Enter US Commercialisation Agreement
30th Jun 20237:00 amRNSFutura Medical - Total Voting Rights
23rd Jun 20234:30 pmRNSRecording of Investor Seminar
22nd Jun 20233:19 pmRNSFutura Medical Annual General Meeting Results
22nd Jun 20237:00 amRNSFutura Medical AGM Statement
19th Jun 202310:25 amRNSCorrection - TR-1: Notification of major holdings
16th Jun 20234:05 pmRNSTR-1: Notification of major holdings
12th Jun 20238:23 amRNSExercise of Warrants
12th Jun 20237:00 amRNSMED3000 Granted US FDA Approval for OTC Sale
8th Jun 20237:00 amRNSFutura Medical Announces Investor Seminar
31st May 20237:00 amRNSBlock Listing Six Monthly Return
26th May 20237:00 amRNSNotice of AGM and availability of Annual Report
24th Apr 20237:00 amRNSTR-1: Notification of major holdings
18th Apr 20237:00 amRNSMED3000, Eroxon® UK Launch
6th Apr 202311:03 amRNSDirectors' / PDMR Dealing and Grant of Options
5th Apr 20237:00 amRNSFull Year Results ended 31 December 2022
29th Mar 20237:00 amRNSUpdate on MED3000 regulatory approval in the US
27th Mar 20235:24 pmRNSNotice of Preliminary Results 2022
14th Mar 20238:33 amRNSMED3000 commercial and US regulatory update
15th Feb 20237:00 amRNSMED3000 FM71 Presentation at ESSM Congress 2023
1st Feb 20231:26 pmRNSBlock Listing Applications to AIM
26th Jan 20237:00 amRNSPre-launch of MED3000 ahead of H1 2023 launch
12th Jan 202311:09 amRNSFutura Remuneration, Options & Total Voting Rights
15th Dec 20223:01 pmRNSTR-1: Notification of major holdings
13th Dec 20221:10 pmEQSFutura Medical 'on track' for launch in H1 2023
13th Dec 20227:00 amRNSFutura Medical announce milestone year for MED3000
30th Nov 20227:00 amRNSFutura Block Listing Six Monthly Return
30th Nov 20227:00 amRNSTotal Voting Rights
21st Oct 20224:40 pmRNSSecond Price Monitoring Extn
21st Oct 20224:35 pmRNSPrice Monitoring Extension
12th Oct 202212:25 pmRNSTR-1: Notification of major holdings
4th Oct 20225:31 pmRNSTotal Voting Rights
3rd Oct 20227:00 amRNSApplication to the US FDA for MED3000
16th Sep 20229:57 amRNSPDMR Dealing and Total Voting Rights
13th Sep 20227:00 amRNSFutura Medical Interim Results 2022
1st Sep 20227:00 amRNSNotice of Interim Results
31st Aug 20227:00 amRNSHighly positive FM71 Phase 3 Study Results
12th Jul 20224:41 pmRNSSecond Price Monitoring Extn
12th Jul 20224:35 pmRNSPrice Monitoring Extension
28th Jun 20223:58 pmRNSFutura Medical AGM Results
28th Jun 20227:00 amRNSFutura Medical AGM Statement
7th Jun 20221:33 pmRNSTR-1: Notification of major holdings
1st Jun 20227:00 amRNSNotice of AGM and Availability of Annual Report
31st May 20227:00 amRNSBlock Listing Six Monthly Return
24th May 202211:40 amRNSTR-1: Notification of major holdings
23rd May 202210:35 amRNSAgreement with Cooper Consumer Health - Correction
23rd May 20227:00 amRNSMED3000 Collaboration in EEA, UK & Switzerland
17th May 20223:56 pmRNSTR-1: Notification of major holdings
16th May 20222:51 pmRNSTR-1: Notification of major holdings
13th May 202212:12 pmRNSTR-1: Notification of major holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.